Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company

Clearmind Medicine, a clinical-stage biotech focused on psychedelic-derived therapeutics, signed a non-binding Letter of Intent to acquire a 51% stake in an EV wireless charging solutions company for $2.5 million. The transaction terms include extending a $1.5 million loan to the target bearing 4% interest; the acquired firm develops proprietary cable-free charging technology up to 10 kW for automated parking systems.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.